We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+9.27%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$49B
AUM Growth
+$3.11B
(+6.8%)
Cap. Flow
+$228M
Cap. Flow
% of AUM
0.47%
Top 10 Holdings %
Top 10 Hldgs %
21.37%
Holding
1,104
New
303
Increased
294
Reduced
324
Closed
153
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$282M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$205M |
| 3 |
ConocoPhillips
COP
|
+$203M |
| 4 |
Fortive
FTV
|
+$200M |
| 5 |
Merck
MRK
|
+$178M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$665M |
| 2 |
ExxonMobil
XOM
|
+$332M |
| 3 |
Burlington
BURL
|
+$242M |
| 4 |
National Vision
EYE
|
+$186M |
| 5 |
CXO
CONCHO RESOURCES INC.
CXO
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.67% |
| 2 | Healthcare | 17.99% |
| 3 | Financials | 14.03% |
| 4 | Consumer Discretionary | 11.97% |
| 5 | Communication Services | 8.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PNTM
201
DELISTED
Pontem Corporation
PNTM
| $52.3M | 0.11% |
+5,400,000
| New | +$52.6M |
|
202
SLB Ltd
SLB
$75.4B
| $51.4M | 0.1% |
1,888,767
-1,444,200
| -43% | -$38M |
|
203
Synchrony
SYF
$25.7B
| $51.3M | 0.1% |
1,262,450
-310,876
| -20% | -$12M |
|
204
MetLife
MET
$61.9B
| $50.9M | 0.1% |
837,526
+44,300
| +6% | +$2.44M |
|
205
KLA
KLAC
$255B
| $50.6M | 0.1% |
1,532,700
-100,000
| -6% | -$3.01M |
|
|
MRSH
206
Marsh
MRSH
$91.4B
| $50.3M | 0.1% |
412,761
+124,400
| +43% | +$14.3M |
|
207
Progressive
PGR
$123B
| $49.3M | 0.1% |
515,285
-122,300
| -19% | -$11.1M |
|
208
KeyCorp
KEY
$24.8B
| $49.2M | 0.1% |
2,461,869
-1,776,841
| -42% | -$34.3M |
|
209
Advanced Micro Devices
AMD
$846B
| $49.2M | 0.1% |
626,534
+14,300
| +2% | +$1.23M |
|
210
OneMain Financial
OMF
$7.53B
| $49.2M | 0.1% |
915,466
-399,544
| -30% | -$20.6M |
|
211
TJX Companies
TJX
$174B
| $48.5M | 0.1% |
733,505
-570,920
| -44% | -$38.2M |
|
212
American Express Global Business Travel
GBTG
$4.93B
| $48.3M | 0.1% |
4,880,885
-974,715
| -17% | -$10.2M |
|
213
Estee Lauder
EL
$31.5B
| $48.3M | 0.1% |
166,084
+99,500
| +149% | +$27.2M |
|
214
Biogen
BIIB
$30.8B
| $48.1M | 0.1% |
171,987
+2,300
| +1% | +$620K |
|
|
B
215
Barrick Mining
B
$64B
| $47.5M | 0.1% |
2,400,000
+400,000
| +20% | +$8.62M |
|
216
Travelers Companies
TRV
$78.7B
| $47.5M | 0.1% |
315,613
+29,700
| +10% | +$4.37M |
|
217
Ross Stores
ROST
$80.5B
| $47.5M | 0.1% |
395,821
+14,801
| +4% | +$1.76M |
|
218
O'Reilly Automotive
ORLY
$74.9B
| $47.3M | 0.1% |
1,398,000
+533,670
| +62% | +$16.5M |
|
219
Ecolab
ECL
$79.7B
| $46.9M | 0.1% |
218,925
-46,499
| -18% | -$9.89M |
|
220
American Electric Power
AEP
$69.9B
| $46.4M | 0.09% |
547,750
+5,000
| +0.9% | +$403K |
|
221
DuPont de Nemours
DD
$19.3B
| $46.3M | 0.09% |
477,443
-91,182
| -16% | -$8.74M |
|
222
Idexx Laboratories
IDXX
$46.4B
| $46M | 0.09% |
94,089
-800
| -0.8% | -$401K |
|
223
Patria Investments
PAX
$1.84B
| $45.9M | 0.09% |
+2,632,387
| New | +$50.5M |
|
224
Xenon Pharmaceuticals
XENE
$6.19B
| $45.6M | 0.09% |
2,550,000
+100,000
| +4% | +$1.69M |
|
225
Cognizant
CTSH
$25.3B
| $45.4M | 0.09% |
581,350
-446,100
| -43% | -$34.5M |
|
Similar funds
Adage Capital Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Adage Capital Partners held 1,104 positions worth $49B, up 6.8% from $45.9B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners's Q1 2021 filing shows 303 new, 294 increased, 324 reduced and 153 closed positions. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 1,500,000 shares worth $325M. The largest sale was Royalty Pharma, an estimated $665M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2021 buy was GW Pharmaceuticals Plc American Depositary Shares: 1,500,000 shares worth $325M.
- Adage Capital Partners added most to Alexion Pharmaceuticals in Q1 2021, an estimated $205M increase.
- Adage Capital Partners's biggest Q1 2021 reduction was Royalty Pharma, cutting an estimated $665M.
- Adage Capital Partners fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $175M.
- Adage Capital Partners's ten largest holdings make up 21% of its $49B portfolio in Q1 2021.
- Adage Capital Partners opened 303 new positions and closed 153 in Q1 2021.
- Adage Capital Partners's portfolio value rose 6.8% quarter-over-quarter to $49B.
Based on Adage Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.